Discontinued Product(±)-ABHD-II (Cat. No. 0977) has been withdrawn from sale for commercial reasons.
Conformationally constrained structural analogue of ACPD.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
References are publications that support the biological activity of the product.
Tellier et al (1995) Synthesis of conformationally-constrained stereospecific analogs of glutamic acid as antagonists of metabotropic receptors. Bio.Org.Med.Chem.Lett. 5 2627
View Related Products by Target
Keywords: (±)-ABHD-II, (±)-ABHD-II supplier, Non-selective, mGlu, 0977, Tocris Bioscience
Citations for (±)-ABHD-II
Citations are publications that use Tocris products.
Currently there are no citations for (±)-ABHD-II .
Reviews for (±)-ABHD-II
There are currently no reviews for this product. Be the first to review (±)-ABHD-II and earn rewards!
Have you used (±)-ABHD-II ?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.